Phaseline

Companies › Taisho Pharmaceutical

Taisho Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 3, 1 Phase 1; Gastroenterology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TS-172
Phosphate binder
–Phase 3Hyperphosphatemia Patients on Hemodialysis; Hyperphosphatemia Patients on Peritoneal Dialysis; Patients With Mild or Moderate Hepatic ImpairmentNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07231029TS-172Phase 1Patients With Mild or Moderate Hepatic ImpairmentGastroenterologyOct 2026
NCT07548840TS-172Phase 3Hyperphosphatemia Patients on HemodialysisGenitourinaryNov 2026
NCT07285291TS-172Phase 3Hyperphosphatemia Patients on HemodialysisGenitourinaryDec 2026
NCT07548853TS-172Phase 3Hyperphosphatemia Patients on Peritoneal DialysisGenitourinaryMay 2027
NCT07285304TS-172Phase 3Hyperphosphatemia Patients on HemodialysisGenitourinaryJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Elgan Pharma Cinclus Pharma Holding Vantive Health Norgine Fertility Center of Las Vegas

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.